Australia's most trusted
source of pharma news
Friday, 19 April 2024
Posted 19 January 2022 PM
GSK says it has received, and rejected, three unsolicited bids for its GSK Consumer Healthcare joint venture with Pfizer, which it plans to spin-off in the middle of this year.
The three bids have come from Unilever, with the latest offer being 50 billion pounds (AUD$95 billion), with 41.7 billion pounds in cash and the rest in Unilever shares.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.